EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Acrokeratosis verruciformis of Hopf: Genetic, clinicopathologic and therapeutic features (Review)

Konstantinos-Antonios Kostopoulos-Kanitakis, Jean Kanitakis

Medicine International · 12.05.2026 · 6 (4) · 1-4

DOI: 10.3892/mi.2026.321 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medicine International, online erschienen am 12.05.2026. Verfasst von Konstantinos-Antonios Kostopoulos-Kanitakis und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, 69152 Pierre-Bénite, France. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acrokeratosis verruciformis of Hopf (AVH) is a rare genodermatosis belonging to the group of epidermal differentiation diseases.It is due to the heterozygous missense mutation p.(Pro602Leu) in the ATPase sarcoplasmic/endoplasmic reticulum Ca 2+ transporting 2 (ATP2A2) gene, which is also involved in Darier disease (DD), and is therefore considered an allelic form of DD.AVH is usually transmitted as an autosomal dominant trait with variable penetrance, although several sporadic cases have been reported.The disease manifests clinically with flat, wart-like papules with a verrucous surface that develop predominantly on the dorsum of the hands and feet, and appear early in life or, in sporadic cases, in adulthood.The lesions exhibit characteristic microscopic changes (verrucous epidermal hyperplasia with a 'church-spire-like' surface), which allow differentiation from DD.The course of the disease is chronic and the outcome as a rule benign, although rare cases of malignant transformation have been reported.Treatment is not necessary; it can be attempted at the request of the patient, knowing that no standardized treatment exists.Treatments that have been tested include topical agents (namely keratolytics, retinoids and cryotherapy) and systemic retinoids; however, the results are often modest.The present brief narrative review aimed to summarize the etiopathogenic, clinical, histopathological and therapeutic features of AVH.

Schlagwörter

Stichwörter der Autor:innen

ATP2A2Darier diseaseHopfacrokeratosis verruciformis

Autor:innen und Institutionen

  • Department of Dermatology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, 69152 Pierre-Bénite, France.
  • Department of Dermatology/CliMA, Ed. Herriot Hospital (Pav. R), Hospices Civils de Lyon, 69437 Lyon cedex 03, France.

Zitieren

APA

Kostopoulos-Kanitakis, K. A., & Kanitakis, J. (2026). Acrokeratosis verruciformis of Hopf: Genetic, clinicopathologic and therapeutic features (Review). Medicine International, 6(4), 1-4. https://doi.org/10.3892/mi.2026.321

Vancouver

Kostopoulos-Kanitakis KA, Kanitakis J. Acrokeratosis verruciformis of Hopf: Genetic, clinicopathologic and therapeutic features (Review). Medicine International. 2026;6(4):1-4. doi:10.3892/mi.2026.321

BibTeX
@article{KostopoulosKanitakis2026,
  author = {Kostopoulos-Kanitakis, Konstantinos-Antonios and Kanitakis, Jean},
  title = {Acrokeratosis verruciformis of Hopf: Genetic, clinicopathologic and therapeutic features (Review)},
  journal = {Medicine International},
  year = {2026},
  volume = {6},
  number = {4},
  pages = {1--4},
  doi = {10.3892/mi.2026.321}
}
Kostenlos starten →